PATENT CLAIM ANALYSIS

Application Number: 16147153
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["424", "451000"]

Abstract:
The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.

Claim (Index 52):
A pharmaceutical composition for oral administration to a subject born with single ventricle heart disease who has undergone Fontan surgery for improving, maintaining or reducing the rate of decline in a clinically relevant measurement that is indicative of the subject's health following the Fontan surgery or for increasing the likelihood of improving, maintaining or reducing the rate of decline in the clinically relevant measurement that is indicative of the subject's health following the Fontan surgery, said pharmaceutical composition comprising:\n udenafil, or a pharmaceutically acceptable salt thereof, in an amount of at least about 125 mg; and a pharmaceutically acceptable excipient; wherein, the subject is a human, whose age ranges between about 12 years old and under about 18 years old; and wherein, the clinically relevant measurement is exercise capacity.

Metadata:
- Claim Count in Document: 113.0
- Percentile: 97.0
- Lexical Diversity: 1.04
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15887523', '14788211', '15197209', '14079548', '15671653']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7289569790994037
- 35 USC 102 Novelty (BERT): 0.6326319521839551
- Combined Prediction Score: 0.7193244764078589
- Mean Citation Score: 447.53735599999993
- Max Citation Score: 837.41754
- Similarity Product: 527.6725247590579

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test